Publications
- PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology2022 | First Faculty of Medicine
- Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics2022 | First Faculty of Medicine
- Terapie inhibitory PCSK9 u pacientů se statinovou intolerancí2019 | First Faculty of Medicine
- Why do we fail when treating dyslipidemia? +12018 | First Faculty of Medicine
- LDL-cholesterol: the lower the better! We need a new lipid lowering drugs? Focus on alirokumab (Praluent)2015 | First Faculty of Medicine
- Familial hypercholesterolemia - past and present. My experiences and findings in our group of patients with familial hypercholesterolemia2014 | First Faculty of Medicine
- Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia2023 | First Faculty of Medicine, Faculty of Science
- Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters2022 | First Faculty of Medicine
- Familial dysbetalipoproteinemia: known unknown2022 | First Faculty of Medicine
- Characteristics of the Czech cohort of patients with familial dysbetalipoproteinemia and evaluation of the applicability of diagnostic algorithms in clinical practice2022 | First Faculty of Medicine
Loading network view...